Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,294 papers from all fields of science
Search
Sign In
Create Free Account
c-Met Inhibitor MSC2156119J
Known as:
MSC2156119J
An orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Receptor Tyrosine Kinase Inhibition
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Abstract 4663: Combination of c-Met inhibitor tepotinib (MSC2156119J) and a third-generation EGFR inhibitor can overcome double resistance mediated by EGFR T790M mutation and c-Met amplification in…
M. Friese-Hamim
,
G. Locatelli
,
F. Bladt
2016
Corpus ID: 78960503
In clinical practice, acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer…
Expand
2015
2015
Abstract 4510: Model-based phase II dose selection of c-Met inhibitor MSC2156119J
W. Xiong
,
S. Bawab
,
+6 authors
P. Girard
2015
Corpus ID: 78187415
Objectives: To evaluate the dose/exposure/target inhibition/tumor growth relationship of MSC2156119J, an orally administered…
Expand
2015
2015
P-118Tepotinib (MSC2156119J) monotherapy in patients with MET-positive advanced hepatocellular carcinoma with Child-Pugh Class A liver function who have failed sorafenib treatment: phase Ib/II trial
S. Faivre
,
E. Raymond
,
U. Stammberger
,
B. Sarholz
,
F. Bladt
2015
Corpus ID: 71093590
2015
2015
2353 Data from a phase Ib/II trial of the oral c-Met inhibitor tepotinib (MSC2156119J) as first-line therapy in Asian patients with advanced hepatocellular carcinoma
S. Qin
,
H. Lim
,
+4 authors
A. Cheng
2015
Corpus ID: 79071572
2015
2015
Abstract 2591: Activity of MSC2156119J in non-small cell lung cancer models with activating EGFR mutation
F. Bladt
,
M. Friese-Hamim
,
A. Blaukat
2015
Corpus ID: 75281600
The therapeutic success of EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC) is hampered…
Expand
2014
2014
Results of the first-in-human phase I trial assessing MSC2156119J (EMD 1214063), an oral selective c-Met inhibitor, in patients (pts) with advanced solid tumors.
G. Falchook
,
David S Hong
,
+10 authors
R. Kurzrock
2014
Corpus ID: 81293024
2521^ Background: MSC2156119J, a selective c-Met inhibitor, suppresses tumor growth in preclinical models. Methods: Primary…
Expand
2014
2014
A multicenter, randomized, phase Ib/II trial of the oral c-Met inhibitor MSC2156119J as monotherapy versus sorafenib in Asian patients with MET-positive (MET+) advanced hepatocellular carcinoma (HCC…
S. Qin
,
A. Cheng
,
+6 authors
G. Massimini
2014
Corpus ID: 80257467
TPS4151 Background: Patients (pts) with HCC have a poor prognosis. Effective treatments are limited, particularly in Asia, which…
Expand
2014
2014
Abstract CT236: MSC2156119J (EMD 1214063), an oral selective c-Met inhibitor, in patients with advanced solid tumors: results of the first-in-human phase I trial
G. Falchook
,
D. Hong
,
+10 authors
R. Kurzrock
2014
Corpus ID: 72296307
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Introduction: Overexpression of the c-Met oncoprotein can…
Expand
2014
2014
450PDFIRST-IN-HUMAN PHASE I TRIAL ASSESSING THE HIGHLY SELECTIVE C-MET INHIBITOR MSC2156119J (EMD 1214063) IN PATIENTS WITH ADVANCED SOLID TUMORS.
G. Falchook
,
D. Hong
,
+7 authors
R. Kurzrock
Annals of Oncology
2014
Corpus ID: 42726783
ABSTRACT Aim: c-Met overexpression is associated with poor clinical prognosis. This dose-escalation study (3 + 3 design…
Expand
2013
2013
Abstract 925: The c-Met inhibitor MSC2156119J effectively inhibits growth of liver cancer models.
F. Bladt
,
A. Blaukat
,
D. Dorsch
,
M. Friese-Hamim
,
M. Meyring
,
O. Schadt
2013
Corpus ID: 74782789
The mesenchymal-epithelial transition factor (c-Met) receptor, also known as hepatocyte growth factor receptor (HGFR), controls…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE